Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Hubei Biocause Pharmaceutical Co stock price, quote, forecast and news

000627.SZ
CNE000000F48

Price

1.67
Today +/-
+0
Today %
+0 %
P

Hubei Biocause Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hubei Biocause Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hubei Biocause Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hubei Biocause Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hubei Biocause Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hubei Biocause Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hubei Biocause Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hubei Biocause Pharmaceutical Co’s growth potential.

Hubei Biocause Pharmaceutical Co Revenue, EBIT and net profit per share

DateHubei Biocause Pharmaceutical Co RevenueHubei Biocause Pharmaceutical Co EBITHubei Biocause Pharmaceutical Co Net Income
202349.37 B undefined329.53 M undefined-651.76 M undefined
202249.18 B undefined1.1 B undefined274.05 M undefined
202149.5 B undefined1.61 B undefined470.71 M undefined
202041.16 B undefined1.17 B undefined580 M undefined
201950.18 B undefined4.1 B undefined1.78 B undefined
201830.94 B undefined2.66 B undefined1.33 B undefined
201753.4 B undefined2.73 B undefined1.33 B undefined
201616.99 B undefined3.49 B undefined1.78 B undefined
20151.09 B undefined464 M undefined247 M undefined
2014806 M undefined-105 M undefined84 M undefined
2013968 M undefined-86 M undefined-101 M undefined
2012780 M undefined-94 M undefined12 M undefined
20111.13 B undefined-89 M undefined-102 M undefined
20101.26 B undefined57 M undefined28 M undefined
2009965 M undefined77 M undefined50 M undefined
2008909 M undefined48 M undefined8 M undefined
2007836 M undefined136 M undefined100 M undefined
2006568 M undefined66 M undefined49 M undefined
2005519 M undefined23 M undefined7 M undefined
2004463 M undefined8 M undefined5 M undefined

Hubei Biocause Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.240.190.260.320.360.350.420.460.520.570.840.910.971.261.130.780.970.811.0916.9953.430.9450.1841.1649.549.1849.37
--19.3333.3325.7810.56-1.9721.209.4612.109.4447.188.736.1630.67-10.07-31.2224.10-16.7434.621,466.18214.26-42.0762.21-17.9920.28-0.640.37
---------------------------
000000000000000000000000000
0.060.030.040.060.060.03-0.040.010.020.070.140.050.080.06-0.09-0.09-0.09-0.110.463.492.732.664.11.171.611.10.33
24.3714.0616.4117.0817.707.74-8.981.734.4311.6216.275.287.984.52-7.85-12.05-8.88-13.0342.7620.555.118.598.172.853.252.230.67
0.060.030.030.040.040.01-0.050.010.010.050.10.010.050.03-0.10.01-0.10.080.251.781.331.331.780.580.470.27-0.65
--45.453.3316.132.78-86.49-1,060.00-110.4240.00600.00104.08-92.00525.00-44.00-464.29-111.76-941.67-183.17194.05620.24-25.460.0833.84-67.34-18.97-41.70-337.59
---------------------------
---------------------------
1.041.191.191.191.191.191.191.191.191.191.191.341.351.351.351.351.351.351.354.264.424.944.944.844.944.944.94
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Hubei Biocause Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hubei Biocause Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hubei Biocause Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hubei Biocause Pharmaceutical Co's financial health and stability.

Assets

Hubei Biocause Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hubei Biocause Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hubei Biocause Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hubei Biocause Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
-2312-54-15-74-4950-655-11-20-1715-81-89-93-93-10,172-42,346-18,179-6,648-9,311-31,810-27,850
0000000000000000000000000
0000000000000000000000000
-5-13-19-24-45-33-15-16-19-26-29-11-24-10-4-7-4-22-42-149-217-1,029-379-613-300
-0.010.05-0.010.04-0.07-0.030.060.050.130.12-0.01-0.020.230.070.090.13-0.12-0.05-2.340.4314.9828.621.424.177.52
-11-99-6-31-146-21-26-25-130-65-362-262-93-149-129-144-186-41-3,678-779-275-717-308-287-135
-0.03-0.07-0.010.01-0.2-0.01-0.05-0.03-0.16-0.08-0.46-0.28-0.01-0.12-0.06-0.180.160.152.59-10.87-9.18-35.04-7.68-15.38-15.62
-0.020.03-00.04-0.050.01-0.02-0-0.03-0.02-0.1-0.020.090.030.07-0.040.340.196.27-10.09-8.9-34.33-7.37-15.1-15.48
0000000000000000000000000
0.020.010.06-0.030.110.04-0.0300.010.050.070.12-0.20.080.070.05-0.07-0.070.976-3.021.470.857.711.76
0000000000000000000000000
0.0400.050.10.10.02-0.05-0.010.08-00.650.11-0.240.060.04-0.01-0.09-0.0810.6310.661.341.130.177.6211.08
0.08-0.01-0.010.1500000.08-0.030.630.01000-0.030.010.019.784.84.67-0.1-0.050.30.01
-620-7-23-16-15-16-14-12-18-52-20-37-22-29-30-31-25-117-148-312-242-634-381-699
0.030.030.10.22-0.130.04-0.020.080.140.180.2-0.190.240.060.260.17-0.080.0818.7543.1540.5330.9644.9932.9938.73
-16-52-116-216-463024-254-375-283132-82-35-13-307-88-6,020-34714,70627,88321,1133,885.487,389.14
0000000000000000000000000

Hubei Biocause Pharmaceutical Co stock margins

The Hubei Biocause Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hubei Biocause Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hubei Biocause Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hubei Biocause Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Hubei Biocause Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hubei Biocause Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hubei Biocause Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hubei Biocause Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hubei Biocause Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hubei Biocause Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hubei Biocause Pharmaceutical Co Margin History

Hubei Biocause Pharmaceutical Co Gross marginHubei Biocause Pharmaceutical Co Profit marginHubei Biocause Pharmaceutical Co EBIT marginHubei Biocause Pharmaceutical Co Profit margin
20230 %0.67 %-1.32 %
20220 %2.24 %0.56 %
20210 %3.25 %0.95 %
20200 %2.85 %1.41 %
20190 %8.17 %3.54 %
20180 %8.59 %4.29 %
20170 %5.11 %2.48 %
20160 %20.55 %10.47 %
20150 %42.76 %22.76 %
20140 %-13.03 %10.42 %
20130 %-8.88 %-10.43 %
20120 %-12.05 %1.54 %
20110 %-7.85 %-8.99 %
20100 %4.52 %2.22 %
20090 %7.98 %5.18 %
20080 %5.28 %0.88 %
20070 %16.27 %11.96 %
20060 %11.62 %8.63 %
20050 %4.43 %1.35 %
20040 %1.73 %1.08 %

Hubei Biocause Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Hubei Biocause Pharmaceutical Co earnings per share therefore indicates how much revenue Hubei Biocause Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hubei Biocause Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hubei Biocause Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hubei Biocause Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hubei Biocause Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hubei Biocause Pharmaceutical Co Revenue, EBIT and net profit per share

DateHubei Biocause Pharmaceutical Co Sales per ShareHubei Biocause Pharmaceutical Co EBIT per shareHubei Biocause Pharmaceutical Co Earnings per Share
20239.99 undefined0.07 undefined-0.13 undefined
20229.95 undefined0.22 undefined0.06 undefined
202110.02 undefined0.33 undefined0.1 undefined
20208.51 undefined0.24 undefined0.12 undefined
201910.16 undefined0.83 undefined0.36 undefined
20186.26 undefined0.54 undefined0.27 undefined
201712.08 undefined0.62 undefined0.3 undefined
20163.99 undefined0.82 undefined0.42 undefined
20150.8 undefined0.34 undefined0.18 undefined
20140.6 undefined-0.08 undefined0.06 undefined
20130.71 undefined-0.06 undefined-0.07 undefined
20120.58 undefined-0.07 undefined0.01 undefined
20110.84 undefined-0.07 undefined-0.08 undefined
20100.93 undefined0.04 undefined0.02 undefined
20090.71 undefined0.06 undefined0.04 undefined
20080.68 undefined0.04 undefined0.01 undefined
20070.7 undefined0.11 undefined0.08 undefined
20060.48 undefined0.06 undefined0.04 undefined
20050.44 undefined0.02 undefined0.01 undefined
20040.39 undefined0.01 undefined0 undefined

Hubei Biocause Pharmaceutical Co business model

Hubei Biocause Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Hubei Biocause Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Hubei Biocause Pharmaceutical Co shares outstanding

The number of shares was Hubei Biocause Pharmaceutical Co in 2023 — This indicates how many shares 4.941 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hubei Biocause Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hubei Biocause Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hubei Biocause Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hubei Biocause Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hubei Biocause Pharmaceutical Co Stock splits

In Hubei Biocause Pharmaceutical Co's history, there have been no stock splits.

Hubei Biocause Pharmaceutical Co dividend history and estimates

In 2023, Hubei Biocause Pharmaceutical Co paid a dividend amounting to 0.11 CNY. Dividend means that Hubei Biocause Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Hubei Biocause Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Hubei Biocause Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Hubei Biocause Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Hubei Biocause Pharmaceutical Co Dividend History

DateHubei Biocause Pharmaceutical Co Dividend
20230.11 undefined
20220.01 undefined
20210.01 undefined
20200.1 undefined
20190.03 undefined
20180.04 undefined
20170.03 undefined
20160.01 undefined
20100.01 undefined
20080.02 undefined

Hubei Biocause Pharmaceutical Co dividend payout ratio

In 2023, Hubei Biocause Pharmaceutical Co had a payout ratio of 34.28%. The payout ratio indicates the percentage of the company's profits that Hubei Biocause Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Hubei Biocause Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Hubei Biocause Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Hubei Biocause Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Hubei Biocause Pharmaceutical Co Payout Ratio History

DateHubei Biocause Pharmaceutical Co Payout ratio
202334.28 %
20229.01 %
202110.5 %
202083.33 %
20198.33 %
201814.81 %
20178.33 %
20162.27 %
201534.28 %
201434.28 %
201334.28 %
201234.28 %
201134.28 %
201042.5 %
200934.28 %
2008150 %
200734.28 %
200634.28 %
200534.28 %
200434.28 %
Unfortunately, there are currently no price targets and forecasts available for Hubei Biocause Pharmaceutical Co.

Eulerpool ESG Scorecard© for the Hubei Biocause Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

7

👫 Social

49

🏛️ Governance

62

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hubei Biocause Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
48.36 % Sunline Group Company Limited2,201,658,17709/30/2023
12.20 % Wang (Wei)555,604,70009/30/2023
11.37 % Liu (Yiqian)517,500,00009/30/2023
1.54 % Wang (Yang Chao)70,323,48809/30/2023
1.02 % Minsheng Royal Fund Management Company Ltd.46,399,066-49,406,2929/30/2023
0.35 % GFund Management Co., Ltd.16,057,80012,221,0009/30/2023
0.34 % Founder Fubon Fund Management Co., Ltd.15,675,900-53,1009/30/2023
0.33 % Zhang (Muxiu)15,000,000-4,372,8009/30/2023
0.30 % Fuli Tianrui Huashang Investment Management Co., Ltd.13,690,99509/30/2023
0.22 % GF Fund Management Co., Ltd.10,127,700565,5006/30/2023
1
2
3
4
5
...
7

Hubei Biocause Pharmaceutical Co Executives and Management Board

Ms. Wenxia Zhou51
Hubei Biocause Pharmaceutical Co Vice Chairman of the Board, General Manager (since 2020)
Compensation 2.02 M
Mr. Dali Chen56
Hubei Biocause Pharmaceutical Co Chief Financial Officer, Director (since 2020)
Compensation 645,000
Mr. Yiqian Liu60
Hubei Biocause Pharmaceutical Co Chairman of the Board (since 2003)
Compensation 300,000
Mr. Fei Long44
Hubei Biocause Pharmaceutical Co Secretary of the Board, Director (since 2012)
Compensation 295,000
Mr. Xiaomiao Zhang47
Hubei Biocause Pharmaceutical Co Independent Director
Compensation 120,000
1
2

Most common questions regarding Hubei Biocause Pharmaceutical Co

What is the P/E ratio of Hubei Biocause Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Hubei Biocause Pharmaceutical Co at the moment.

What is the P/S ratio of Hubei Biocause Pharmaceutical Co 2024?

The P/S cannot be calculated for Hubei Biocause Pharmaceutical Co currently.

What is the AlleAktien quality score of Hubei Biocause Pharmaceutical Co?

The AlleAktien quality score for Hubei Biocause Pharmaceutical Co is 3/10.

What is the revenue of Hubei Biocause Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Hubei Biocause Pharmaceutical Co.

How high is the profit of Hubei Biocause Pharmaceutical Co 2024?

The profit cannot currently be calculated for Hubei Biocause Pharmaceutical Co.

What is the business model of Hubei Biocause Pharmaceutical Co

No history available for Hubei Biocause Pharmaceutical Co.

What is the Hubei Biocause Pharmaceutical Co dividend?

Hubei Biocause Pharmaceutical Co pays a dividend of 0.01 CNY distributed over payouts per year.

How often does Hubei Biocause Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Hubei Biocause Pharmaceutical Co or the company does not pay out a dividend.

What is the Hubei Biocause Pharmaceutical Co ISIN?

The ISIN of Hubei Biocause Pharmaceutical Co is CNE000000F48.

What is the Hubei Biocause Pharmaceutical Co ticker?

The ticker of Hubei Biocause Pharmaceutical Co is 000627.SZ.

How much dividend does Hubei Biocause Pharmaceutical Co pay?

Over the past 12 months, Hubei Biocause Pharmaceutical Co paid a dividend of 0.11 CNY . This corresponds to a dividend yield of about 6.59 %. For the coming 12 months, Hubei Biocause Pharmaceutical Co is expected to pay a dividend of 0.11 CNY.

What is the dividend yield of Hubei Biocause Pharmaceutical Co?

The current dividend yield of Hubei Biocause Pharmaceutical Co is 6.59 %.

When does Hubei Biocause Pharmaceutical Co pay dividends?

Hubei Biocause Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, July, June.

How secure is the dividend of Hubei Biocause Pharmaceutical Co?

Hubei Biocause Pharmaceutical Co paid dividends every year for the past 8 years.

What is the dividend of Hubei Biocause Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0.11 CNY are expected. This corresponds to a dividend yield of 6.59 %.

In which sector is Hubei Biocause Pharmaceutical Co located?

Hubei Biocause Pharmaceutical Co is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Hubei Biocause Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Biocause Pharmaceutical Co from 5/30/2023 amounting to 0.11 CNY, you needed to have the stock in your portfolio before the ex-date on 5/30/2023.

When did Hubei Biocause Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 5/30/2023.

What was the dividend of Hubei Biocause Pharmaceutical Co in the year 2023?

In the year 2023, Hubei Biocause Pharmaceutical Co distributed 0.005 CNY as dividends.

In which currency does Hubei Biocause Pharmaceutical Co pay out the dividend?

The dividends of Hubei Biocause Pharmaceutical Co are distributed in CNY.

All fundamentals about Hubei Biocause Pharmaceutical Co

Our stock analysis for Hubei Biocause Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Biocause Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.